



Kingsoft Corporation (3888 HK)

Last price: HK\$25.66

Support levels: HK\$23.80/HK\$22.84

Resistance levels: HK\$27.96/HK\$32.30

Technical View:

Price action is gradually rounding out a structural base, forming a potential rounding bottom pattern while actively testing its primary overhead resistance boundary. The RSI maintains its position above its neutral 50-midline to reflect building underlying strength. This favours a high-conviction breakout above this critical supply ceiling, which would formally validate the pattern and initiate a strong upward momentum phase towards higher targets.

Average timeframe: Around two weeks.



Hansoh Pharmaceutical Group (3692 HK)

Last price: HK\$33.52

Support levels: HK\$32.02/HK\$31.36

Resistance levels: HK\$37.76/HK\$39.64

Technical View:

Price has delivered a decisive bullish candle breakout from a pennant continuation pattern. The RSI holds firmly above its neutral 50-midline and is curling upward to reflect accelerating directional momentum. This favours continued mark-up, projecting further upside progression towards higher resistance targets as long as the pennant breakout zone remains defended on any brief pullbacks.

Average timeframe: Around two weeks.

Analyst

Greater China Research Team

research-hk@uobkh.com

Tham Mun Hon, CFA

+852 2236 6799

munhon.tham@uobkh.com

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at the following link:
<https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87> or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."